115 related articles for article (PubMed ID: 10676721)
21. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation.
Haas M; Leko-Mohr Z; Roschger P; Kletzmayr J; Schwarz C; Mitterbauer C; Steininger R; Grampp S; Klaushofer K; Delling G; Oberbauer R
Kidney Int; 2003 Mar; 63(3):1130-6. PubMed ID: 12631097
[TBL] [Abstract][Full Text] [Related]
22. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation.
Torres A; García S; Gómez A; González A; Barrios Y; Concepción MT; Hernández D; García JJ; Checa MD; Lorenzo V; Salido E
Kidney Int; 2004 Feb; 65(2):705-12. PubMed ID: 14717945
[TBL] [Abstract][Full Text] [Related]
23. The effect of low-dose cholecalciferol and calcium treatment on posttransplant bone loss in renal transplant patients: a prospective study.
Sahin G; Yasar NS; Sirmagul B; Bal C; Yalcin AU
Ren Fail; 2008; 30(10):992-9. PubMed ID: 19016151
[TBL] [Abstract][Full Text] [Related]
24. Early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation.
Brandenburg VM; Politt D; Ketteler M; Fassbender WJ; Heussen N; Westenfeld R; Freuding T; Floege J; Ittel TH
Transplantation; 2004 May; 77(10):1566-71. PubMed ID: 15239623
[TBL] [Abstract][Full Text] [Related]
25. Hypophosphatemia in long-term renal transplant recipients: effects on bone histology and 1,25-dihydroxycholecalciferol.
Felsenfeld AJ; Gutman RA; Drezner M; Llach F
Miner Electrolyte Metab; 1986; 12(5-6):333-41. PubMed ID: 3543636
[TBL] [Abstract][Full Text] [Related]
26. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
[TBL] [Abstract][Full Text] [Related]
27. Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation.
Westeel FP; Mazouz H; Ezaitouni F; Hottelart C; Ivan C; Fardellone P; Brazier M; El Esper I; Petit J; Achard JM; Pruna A; Fournier A
Kidney Int; 2000 Oct; 58(4):1788-96. PubMed ID: 11012914
[TBL] [Abstract][Full Text] [Related]
28. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
29. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
Shane E; Addesso V; Namerow PB; McMahon DJ; Lo SH; Staron RB; Zucker M; Pardi S; Maybaum S; Mancini D
N Engl J Med; 2004 Feb; 350(8):767-76. PubMed ID: 14973216
[TBL] [Abstract][Full Text] [Related]
30. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
Wang SX; Li H
Chin Med J (Engl); 2008 Jul; 121(14):1280-4. PubMed ID: 18713548
[TBL] [Abstract][Full Text] [Related]
31. Potential effects of 1,25-dihydroxyvitamin D3 in renal transplant recipients.
Sezer S; Uyar M; Arat Z; Ozdemir FN; Haberal M
Transplant Proc; 2005 Sep; 37(7):3109-11. PubMed ID: 16213322
[TBL] [Abstract][Full Text] [Related]
32. Prevention of bone loss in paraplegics over 2 years with alendronate.
Zehnder Y; Risi S; Michel D; Knecht H; Perrelet R; Kraenzlin M; Zäch GA; Lippuner K
J Bone Miner Res; 2004 Jul; 19(7):1067-74. PubMed ID: 15176988
[TBL] [Abstract][Full Text] [Related]
33. Long-term changes in bone mineral density in kidney transplant recipients.
Naylor KL; Garg AX; Hodsman AB; Rush DN; Leslie WD
Transplantation; 2014 Dec; 98(12):1279-85. PubMed ID: 25050472
[TBL] [Abstract][Full Text] [Related]
34. Eldecalcitol and calcitriol stimulates 'bone minimodeling,' focal bone formation without prior bone resorption, in rat trabecular bone.
Saito H; Takeda S; Amizuka N
J Steroid Biochem Mol Biol; 2013 Jul; 136():178-82. PubMed ID: 23069645
[TBL] [Abstract][Full Text] [Related]
35. [Hemodialysis with 2.5 mEq/L of calcium in relative hypoparathyroidism: long-term effects on bone mass].
Sánchez Perales MC; García Cortés MJ; Borrego FJ; Fernández Martínez S; Borrego J; Pérez del Barrio P; Liébana A; Pérez Bañasco V
Nefrologia; 2000; 20(3):254-61. PubMed ID: 10917002
[TBL] [Abstract][Full Text] [Related]
36. Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate.
Freemont T; Malluche HH
Clin Nephrol; 2005 Feb; 63(2):138-45. PubMed ID: 15730056
[TBL] [Abstract][Full Text] [Related]
37. A prospective study of bone loss and turnover after cardiac transplantation: effect of calcium supplementation with or without calcitonin.
Välimäki MJ; Kinnunen K; Tähtelä R; Löyttyniemi E; Laitinen K; Mäkelä P; Keto P; Nieminen M
Osteoporos Int; 1999; 10(2):128-36. PubMed ID: 10501793
[TBL] [Abstract][Full Text] [Related]
38. A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus.
Yeap SS; Fauzi AR; Kong NC; Halim AG; Soehardy Z; Rahimah I; Chow SK; Goh EM
J Rheumatol; 2008 Dec; 35(12):2344-7. PubMed ID: 19004038
[TBL] [Abstract][Full Text] [Related]
39. The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study.
Drake WM; Rodríguez-Arnao J; Weaver JU; James IT; Coyte D; Spector TD; Besser GM; Monson JP
Clin Endocrinol (Oxf); 2001 Apr; 54(4):525-32. PubMed ID: 11318789
[TBL] [Abstract][Full Text] [Related]
40. Changes in bone mineral density and selected metabolic parameters over 24 months following renal transplantation.
Al-Gabri S; Zadrazil J; Krejcí K; Horák P; Bachleda P
Transplant Proc; 2005 Mar; 37(2):1014-9. PubMed ID: 15848609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
